UPS Invests $48 Million in Global Cold Chain Expansion to Meet Surging Biologics Demand
核心洞察
UPS (搜索) commits $48 million to expand temperature-controlled freight cross-dock facilities across 27 locations in Europe, Asia, and the Americas.
The investment targets the growing $39.1 billion temperature-sensitive biologics market, driven by GLP-1 (搜索) injectables, cell and gene therapies, and mRNA platforms.
Temperature control failures account for 50% of global vaccine waste and cost an estimated $35 billion annually, according to the World Health Organization.
UPS (搜索) has announced a $48 million investment to expand its temperature-controlled freight cross-dock facilities across 27 locations in Europe, Asia, and the Americas, positioning the logistics giant to capture a growing share of the $39.1 billion temperature-sensitive biologics market.
The expansion targets short-term storage capabilities between air and ground transportation for pharmaceuticals requiring strict thermal management. According to Growth Market Reports, demand for temperature-sensitive biologics is projected to reach $39.1 billion through 2033, fueled by the rapid proliferation of cell and gene therapies, mRNA platforms, and GLP-1 (搜索) injectables.
"We have aligned our investments with our Healthcare customers' specialised needs," said Kate Gutmann, EVP and President of International, Healthcare and Supply Chain Solutions at UPS (搜索). "Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world."
The Cost of Cold Chain Failure
The stakes for maintaining pharmaceutical cold chains are substantial. The World Health Organization reports that temperature failures contribute to up to 50% of global vaccine waste, carrying an estimated annual cost of $35 billion. Medicines typically require maintenance within two to eight degrees Celsius, frozen conditions, or 15°C to 25°C throughout transit, and deviations from these ranges can compromise drug efficacy and patient safety.
PharmaSource data indicates that approximately one in three newly approved drugs is a biologic, and more than 85% of these require temperature-controlled handling because they are created from living cells.
GLP-1 (搜索) Demand Drives Market Growth
GLP-1 (搜索) injectables represent a particularly significant driver of cold chain demand. According to KFF data from November 2025, one in eight adults reported using GLP-1 medications to treat diabetes, weight loss, or another condition. Pharmaceutical companies have raced to meet growing demand, with Eli Lilly announcing in March plans to invest $3 billion over the next decade to expand manufacturing in China, primarily to increase production capacity for orforglipron, the company's experimental GLP-1 receptor agonist.
Demand is expected to accelerate further. Starting July 1, Medicare beneficiaries may be able to obtain certain GLP-1 (搜索) prescriptions for $50 per month under a new Centers for Medicare & Medicaid Services initiative.
Healthcare as a Recession-Proof Strategy
UPS (搜索)'s cold chain expansion reflects a broader strategic pivot toward healthcare logistics among major freight carriers seeking insulation from economic volatility. "There have been lots of challenges over the past several years—high inflation, contractions in markets—but healthcare continues to grow," UPS CEO Carol Tomé told Reuters in April. "I would argue that healthcare is pretty recession-proof."
The strategy appears to be yielding results. During the company's first-quarter earnings call in April, Tomé reported that UPS (搜索)'s global healthcare portfolio has gained market share every year since 2021, generating $3 billion in revenue in a single quarter for the first time.
The investment follows UPS (搜索)'s January acquisition of Frigo-Trans (搜索) and BPL, European healthcare logistics companies specializing in cold-chain transportation, and the November 2025 acquisition of Andlauer Healthcare Group (搜索) for $1.6 billion.
Integrated Network and Real-Time Monitoring
UPS (搜索) operates more than 19.2 million square feet of cGMP and GDP-compliant healthcare distribution space globally, handling inventory management, cold chain packaging and shipping, storage and fulfillment of medical devices, as well as lab and clinical trial logistics across more than 200 countries and territories.
The company employs a 24/7/365 control tower that monitors shipments, identifies risks, and supports intervention to maintain product movement, providing customers with real-time oversight for each shipment.
"Biologics and personalised treatments are driving better, more targeted care for patients," said John Bolla, President of UPS (搜索) Healthcare. Gutmann added: "This effort—and all of our work in healthcare logistics—extends from a deep understanding that we're doing more than moving packages. We are helping patients access the medications and treatments they need."
Industry-Wide Trend
FedEx (搜索) is pursuing a similar strategy, onboarding a healthcare-focused vice president of quality with experience in global healthcare logistics earlier this year. FedEx ended its 2024 fiscal year with approximately $9 billion in healthcare revenue. "To attract new business in pharma, where we are currently under-penetrated, we are enhancing our offering to serve the specialised, unique needs of our customers with extreme emphasis on quality," FedEx Chief Customer Officer Brie Carere told investors in March.